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Abstract
We recently isolated a proteoglycan form of macrophage
colony-stimulating factor (PG-M-CSF) that carries a chon-
droitin sulfate glycosaminoglycan chain. Here, we examined
the interaction of PG-M-CSF with low density lipoprotein
(LDL). When LDL preincubated with PG-M-CSF was frac-
tionated by molecular size sieving chromatography, it was
eluted earlier than untreated LDL. When LDL was preincu-
bated with chondroitin sulfate-free 85-kD M-CSF instead
of PG-M-CSF, the elution profile of LDL remained un-
changed, indicating specific interaction between PG-M-CSF
and LDL. The level of PG-M-CSF binding in the wells of a
plastic microtitration plate precoated with LDL was signifi-
cant, this binding being completely abolished by pretreat-
ment of PG-M-CSF with chondroitinase AC, which de-
grades chondroitin sulfate. The addition of exogeneous
chondroitin sulfate or apolipoprotein B inhibited the bind-
ing ofPG-M-CSF to LDL in a dose-dependent manner, indi-
cating that the interaction between PG-M-CSF and LDL
was mediated by the binding of the chondroitin sulfate chain
of PG-M-CSF to LDL apolipoprotein B. PG-M-CSF was
also demonstrated in the arterial wall, and there were in-
creased amounts of PG-M-CSF in atherosclerotic lesions.
The in vitro interaction between PG-M-CSF and LDL thus
appears to have physiological significance. (J. Clin. Invest.
1994. 94:1637-1641.) Key words: colony-stimulating factor
* chondroitin sulfate * glycosaminoglycan - atherosclerosis
* macrophage
Introduction
Proteoglycans (PG)' are macromolecules composed of various
kinds of glycosaminoglycan (GAG) chains and various kinds
of core proteins, whose moieties are covalently bound with each
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other (1, 2). Common GAG include heparan sulfate, chondroi-
tin sulfate, dermatan sulfate, and keratan sulfate ( 1, 2), the core
proteins of these being different. The PG are a highly diverse
group of macromolecules; in only a limited number has the
molecular structure been established (1, 2).
PG are widely distributed in animal tissues. The increased
amounts of certain arterial PG in atherosclerotic aortas and their
affinity for low density lipoprotein (LDL) have lead various
investigators to suggest that these PG are involved in the athero-
sclerotic process (3-7). Supporting evidence for the involve-
ment of the PG-LDL complex in the atherosclerotic process
has been provided by the isolation of this complex from human
vascular lesions (8). Interaction between PG and LDL is
thought to be mediated by the binding of anionic GAG chains
to the positively charged amino acid of apolipoprotein B (3-
7). However, previous studies have also indicated that both
core proteins and GAG are essential for the formation of these
complexes and that the potential of PG to interact with LDL
depends on the nature of the core proteins and on the composi-
tions of the GAG (4, 8, 9). The interaction between PG mole-
cules and LDL is important in the pathogenesis of atherosclero-
sis, since this interaction may facilitate the trapping of LDL in
the arterial wall or cause structural alterations in the LDL pro-
tein, alterations that influence the uptake of lipoprotein by the
arterial mesenchyma (10-16). To date, however, no specific
PG molecule involved in LDL binding has been characterized
yet. To clarify the precise role of PG in the pathogenesis of
atherosclerosis, it is important to identify PG molecules with
such functions.
Macrophage colony-stimulating factor (M-CSF), a growth
factor for mononuclear phagocytic cells (17), was first identi-
fied as a glycoprotein with a molecular mass of 85 kD (18,
19). A second M-CSF molecule, with a molecular mass of
> 200 kD, and which carries chondroitin sulfate GAG, has since
been identified by us and others (20, 21); this was designated
"proteoglycan form of M-CSF" (PG-M-CSF) (22). Human
M-CSF is produced as a 522-amino acid polypeptide preceded
by a 32-amino acid signal peptide (19). The precursor poly-
peptides are rapidly dimerized via disulfide bonds and transla-
tionally glycosylated (19). Proteolytic cleavage at the residue
around 223 produces an M-CSF subunit of 43 kD (19). The
85-kD M-CSF is a homodimer of the 43-kD subunit (19). In
contrast, proteolytic cleavage occurring at the residue around
400, but not at that around 223, produces a PG-M-CSF-specific
subunit with a molecular mass of 150-200 kD (20, 21). In
addition to having a longer carboxyl terminus than the 43-kD
subunit, the PG-M-CSF-specific subunit contains a chondroitin
sulfate chain on the COOH-terminal portion (21). It has also
been shown that the combination of the PG-M-CSF-specific
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subunit with the identical subunit or the 43-kD subunit lacking
the COOH-terminal structures yielded homodimeric or hetero-
dimeric PG-M-CSF, respectively (22). Here, we show the ca-
pacity of this newly identified PG, i.e., PG-M-CSF, to bind
plasma LDL.
Methods
Materials. The 85-kD M-CSF and PG-M-CSF were purified from media
conditioned with Chinese hamster ovary cells transfected with human
M-CSF cDNA (19, 21, 22). Human LDL (d = 1.019-1.063 g/ml) was
prepared by ultracentrifugation from normal plasma. Chondroitin sulfate
A (whale cartilage), chondroitin sulfate B (hog skin), chondroitin sul-
fate C (shark cartilage), and heparan sulfate (bovine kidney) were
purchased from Seikagaku Kogyo Co., Ltd. (Tokyo, Japan); purified
human apolipoprotein B was purchased from Chemicon International,
Inc. (Temecula, CA).
Formation ofPG-M-CSF and LDL complex. Two types of associa-
tions between PG-M-CSF and LDL were explored.
First, soluble complexes were obtained by mixing solutions of LDL
with solutions of M-CSF. LDL (100 og protein), 85-kD M-CSF (100
jig), or PG-M-CSF (100 jig protein) was dissolved in 1 ml of phos-
phate-buffered saline (PBS). LDL (100 jig) was mixed with 85-kD M-
CSF (100 ,ug) or PG-M-CSF (100 jig) and dissolved in 1 ml of PBS.
These solutions were left at 370C for 2 h. A 10-Ml aliquot of each
solution was loaded on a TSK G3000SW column (Toyo Soda, Tokyo,
Japan) and then eluted with 10mM Tris-HCl buffer (pH 7.4) containing
150 mM NaCl. Fractions (400 0l/fraction) were monitored for ab-
sorbance at 280 nm (23) and assayed for M-CSF content using an M-
CSF-specific enzyme-linked immunosorbent assay (ELISA) (22, 24).
Second, the binding of PG-M-CSF to immobilized LDL was exam-
ined. LDL (10 Mg protein/ml in PBS) was added to the wells (0.1 ml/
well) of a microtiter plate (3950; Costar Corp., Cambridge, MA), and
the plate was incubated for 1 h at 37°C (7, 22). The wells were then
washed three times with PBS. All washing steps described below were
done in the same manner. After the washing, the uncoated sites of the
wells were blocked by incubation with 3% bovine serum albumin (BSA)
in PBS for 90 min. After further washing, samples dissolved in interac-
tion buffer (10 mM Tris-HCl buffer, pH 7.0, containing 1.5% BSA and
10 mM CaCl2) were then added to the coated wells, and incubation was
carried out for 1 h at 37°C. We included CaCl2 (10 mM) in the interac-
tion buffer, since it had been reported in an earlier study that optimal
binding between PG and LDL was obtained in the presence of divalent
cations (7). In some experiments, PG-M-CSF was pretreated with chon-
droitinase AC (10 mU/ml, EC 4.2.2.4; Seikagaku Kogyo Co., Ltd.) ( 12,
13) and then added to the wells, as outlined above. Potent inhibitors
such as GAGs, soluble LDL, or apolipoprotein B were added to the
PG-M-CSF solution immediately before the mixture was added to the
wells. To keep apolipoprotein B soluble, we included sodium deoxycho-
late in the interaction buffer, at a final concentration of 10 mM, to the
mixture of apolipoprotein B and PG-M-CSF, according to the manufac-
turer's instructions. The wells were then washed, anti-M-CSF rabbit
IgG dissolved in PBS containing 1.5% BSA was added, and the plate
was further incubated for 1 h at 37°C. The plate was then washed,
horseradish peroxidase-conjugated goat IgG against rabbit IgG (Bio-
Rad Laboratories, Richmond, CA), dissolved in PBS containing 1.5%
BSA, was added, and the plate was incubated for another 1 h at 37°C.
After a final washing, freshly prepared O-phenylenediamine dihydro-
chloride solution was added, and the color development of the solutions
in the wells was measured with absorbance at 492 nm, using a microplate
reader (Bio-Rad Laboratories).
Characterization of arterial M-CSF. The purified M-CSF prepara-
tions (1 Mg each) were dialyzed against buffer A (25 mM Tris-HCl,
pH 7.4, containing 0.5% CHAPS and 6 M urea) and then applied to a
1-ml DEAE-Sephacel (Pharmacia LKB Biotechnology Inc., Piscataway,
NJ) column previously equilibrated with buffer A. The column was
washed stepwisely with 2 ml of buffer A, containing 0.1, 0.2, 0.3, 0.4,
0.5, 0.6, 0.7, or 0.8 M NaCl. The fractions, at a 1:1,000 dilution, were
then assayed for M-CSF content (22, 23). The purified M-CSF prepara-
tions were also analyzed by gradient (4-20% acrylamide) SDS-PAGE
under nonreduced conditions, followed by immunoblotting (21, 24).
Aortas were obtained at autopsy from five patients with atherosclerosis,
after family members had given their informed consent. The intimal
layers of the normal and atherosclerotic regions were peeled off and
weighed. 10 ml of ice-cold extraction buffer (25 mM Tris-HCl buffer,
pH 7.4, containing 6 M urea, 1 M NaCl, 0.5% CHAPS, 10 mM EDTA,
1 mM phenylmethylsulfonyl fluoride, 5 mM benzamidine-HCl, and 10
mM aminocaproic acid) was poured over 1 g of the tissues. The tissues
were then finely minced with scissors and extracted for 24 h at 40C.
After centrifugation, the supernatants (tissue extracts) were collected.
Each extract or normal serum (1 ml) was dialyzed against buffer A,
loaded onto a 2.5-ml DEAE-Sephacel column, and then eluted step-
wisely with 5 ml buffer, as outlined above. The fractions, at a 1:10
dilution, were then assayed for M-CSF content with an ELISA.
Results
If PG-M-CSF and LDL formed a complex, it would be expected
that this complex would have a greater molecular size than
noncomplexed LDL. To confirm this, we compared the elution
profiles ofLDL and LDL preincubated with PG-M-CSF in PBS
on a TSK G3000SW column (Toso, Tokyo, Japan). Taking
advantage of the nature of lipoproteins, i.e., their relatively high
value of absorbance at 280 nm (23), we analyzed each fraction
for LDL content by measuring absorbance at 280 nm. As shown
in Fig. 1 a, LDL preincubated with PG-M-CSF was eluted in
the inclusive volume of the column, with an elution time earlier
than that of untreated LDL, indicating the formation of a com-
plex between PG-M-CSF and LDL. Acetylated LDL preincu-
bated with PG-M-CSF was also eluted earlier than untreated
acetylated LDL (data not shown). In contrast, LDL preincu-
bated with 85-kD M-CSF had the same elution profile as that
of untreated LDL (Fig. 1 a). Each fraction was also assayed
for M-CSF content by ELISA (Fig. 1 b). LDL-treated 85-kD
M-CSF had the same elution position as the 85-kD M-CSF,
indicating no specific interaction between 85-kD M-CSF and
LDL. On the other hand, PG-M-CSF mixed with LDL was
eluted as a broad peak with a later elution time than the untreated
PG-M-CSF.
We next examined, using a modified ELISA (22, 24), the
binding of PG-M-CSF to LDL previously adsorbed onto the
wells of a plastic microtitration plate. There was no significant
binding of PG-M-CSF to wells not coated with LDL (data not
shown), and there was no significant binding of the 85-kD M-
CSF to wells coated with LDL, while PG-M-CSF exhibited an
appreciable capacity to bind LDL (Fig. 2 a). Pretreating PG-M-
CSF with chondroitinase AC, which degrades the chondroitin
sulfate chains of PG-M-CSF, completely abolished the binding
(Fig. 2 a). When added to the interaction mixture, various
GAG species, including three chondroitin sulfate preparations,
inhibited PG-M-CSF binding to the immobilized LDL (Fig. 2
b). Heparan sulfate also inhibited the binding, but its inhibition
was less effective than that of chondroitin sulfate GAG (Fig. 2
b). As shown in Fig. 2 c, the interaction of PG-M-CSF with
immobilized LDL was partly inhibited by the addition of soluble
LDL; apolipoprotein B, a protein present in LDL, also exhibited
efficient inhibitory activity. Taken together, these findings indi-
cate that the interaction between PG-M-CSF and LDL was me-
diated by the binding of PG-M-CSF chondroitin sulfate to LDL
apolipoprotein B.
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Figure 1. Chromatography of LDL and LDL preincubated with M-CSF
on a TSK G3000SW column. LDL, 85-kD M-CSF (85kD), PG-M-CSF
(PG), LDL preincubated with 85-kD M-CSF (LDL+85kD), or LDL
preincubated with PG-M-CSF (LDL+PG) were eluted on a TSK
G3000SW column. The eluted fractions were monitored for absorbance
at 280 nm (a) or assayed for M-CSF content using an ELISA (b). No
detectable peak was observed when 85-kD M-CSF and PG-M-CSF
fractions were monitored for absorbance at 280 nm, and no significant
amounts of M-CSF were detected when LDL fractions were assayed
with an M-CSF-specific ELISA. The void-volume fraction is No. 13.
Our hypothesis, that PG-M-CSF may bind LDL in the arte-
rial wall in vivo, was supported by the detection of PG-M-CSF
in the arterial wall (Fig. 3). The 85-kD M-CSF and PG-M-
CSF showed different behavior on DEAE-Sephacel ion-ex-
change column chromatography (20-22). As shown in Fig. 3
a, the purified 85-kD M-CSF (inset) was eluted mainly at 0.2
M NaCl concentration, while the purified PG-M-CSF (inset)
was eluted mainly at 0.4 M NaCl concentration. Using this
system, we characterized the M-CSF species present in normal
human serum and aortic extracts. The majority of serum M-
CSF was eluted at 0.2M NaCl, and there was a faint appearance
of M-CSF at 0.4 M NaCl (Fig. 3 b), indicating that the 85-kD
M-CSF was the major M-CSF species in human serum. The
extracts of normal aortic tissue contained M-CSF at a concentra-
tion of 1.66-+0.42 ng/g tissue (n = 5), and the extracts of
atherosclerotic intima contained higher amounts of M-CSF
(4.04-+1.14 ng/g tissue, n = 5) than those from the normal
region. The difference of the M-CSF amount between normal
region and atherosclerotic region was statistically significant at
the level of P < 0.002 (Student's t test). The M-CSF species
in the extract of normal aorta was eluted at 0.2 M NaCl, and
there was also a second peak observed at 0.4 M NaCl, with a
0.5 a Figure 2. Binding of PG-M-CSF to immobilized
E
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Chon) were diluted at the
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and the plate was pro-
cessed as indicated in a. The level of binding in the presence of a
potential inhibitor was compared with the control binding obtained in
its absence and was expressed as a percentage of the control binding.
The PG-M-CSF samples without the potent inhibitors in b and c showed
absorbances of 0.35 and 0.55, respectively.
trailing shoulder at 0.5 M NaCl (Fig. 3 c). There was no sig-
nificant change in the M-CSF elution pattern of atherosclerotic
intimal extract compared with that of the normal aorta, but both
peaks contained approximately twofold larger amounts of M-
CSF than those in the normal aorta (Fig. 3 d). The first peak at
0.2 M NaCl corresponding to 85-kD M-CSF of atherosclerotic
region contained 0.77±0.32 ng M-CSF, which was higher than
that of normal region (0.43±0.10 ng) with a statistical signifi-
cance at the level of P < 0.05. Similarly, the second peak at
0.4 M NaCl corresponding to PG-M-CSF of atherosclerotic
region contained 0.66±0.16 ng M-CSF, which was higher than
that of normal region (0.34±0.08 ng) with a statistical signifi-
cance at the level of P < 0.004. These findings indicated that
both 85-kD M-CSF and PG-M-CSF were present in the arterial
wall and that both types ofM-CSF were increased in atheroscle-
rotic lesions.
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Figure 3. Chromatography of purified M-
CSFs, sera, and extracts of aortic intima on
DEAE-Sephacel column. The purified 85-kD
M-CSF (hatched bars) and PG-M-CSF
(open bars) (a), sera from five normal vol-
unteers (b), extracts of normal intima ob-
tained from normal aortic region of five pa-
tients with atherosclerosis (c), and extracts
of intima obtained from atherosclerotic re-
gion from the same individuals (d) were
loaded onto DEAE-Sephacel column. The
bound materials were eluted through the col-
umn stepwisely with buffers containing in-
creasing concentrations of NaCl. The con-
centration of NaCl is indicated on the ab-
scissa. The eluted fractions were assayed for
M-CSF content, using an ELISA. The 85-kD
M-CSF and PG-M-CSF were analyzed by
SDS-PAGE, followed by immunoblotting (a,
inset).
Discussion
Evidence for the existence, in vivo, of the LDL-PG complex
has been obtained in biochemical and histochemical studies of
aortic lesions (8, 10). The in vitro interaction between LDL
and PG extracted from aorta has also been demonstrated in
numerous studies (3-7). However, many other aspects of this
important interaction remain to be investigated. For example,
Vijayagopal et al. (4) found that the binding of free GAG chains
to LDL was weaker than that of the parental PG, while Mourao
et al. (5) showed that removal of the core protein of aortic PG
did not affect the interaction of the PG with LDL. The mecha-
nism whereby macrophage uptake of the LDL-PG complex
occurs, however, is not clear; one group reported that LDL
modified by PG was metabolized via apolipoprotein B receptors
( 16), while another reported that the complex was metabolized
via a scavenger-receptor pathway (25). These discrepancies
could be due to differences in assay conditions or PG prepara-
tions. Most of these studies were done with unfractionated or
partially fractionated PG extracted from the aorta. In our study,
we clearly showed the affinity of PG-M-CSF and LDL (Figs.
1 and 2). To our knowledge, this study represents the first
characterization of a specific proteoglycan molecule involved
in the binding of LDL. It is possible that the apparent reduction
in molecular size of PG-M-CSF preincubated with LDL (Fig.
1 b) is due to structural alterations in the linear GAG chain
induced by LDL binding, since the interaction between PG-
M-CSF and LDL is mediated by the binding of PG-M-CSF
chondroitin sulfate GAG chains to LDL (Fig. 2, a and b).
However, the underlying mechanism in this phenomenon re-
mains to be determined. In any case, the finding supports the
conclusion that PG-M-CSF and LDL interact and form a com-
plex.
Earlier studies have demonstrated the importance of M-CSF
in the atherosclerotic process. First, several recent studies have
reported the elevated expression of the M-CSF gene in vascular
cell components of atherosclerotic lesions, including endothelial
cells, monocytes/macrophages, and smooth muscle cells (26-
29). Our findings presented here, i.e., the presence of PG-M-
CSF and the 85-kD M-CSF in the aortic tissue and the increased
amounts of these M-CSF in atherosclerotic lesions (Fig. 3, c
and d), are in accordance with these observations. Since little
PG-M-CSF was present in serum (Fig. 3 b), the increment of
PG-M-CSF amount in atherosclerotic lesions might reflect the
coaccumulation of PG-M-CSF with LDL. Second, it has been
reported that the 85-kD M-CSF stimulates lipoprotein lipase
secretion from macrophages and that it enhances both the uptake
and efflux of cholesterol in human monocyte-derived macro-
phages (30). Both PG-M-CSF and the 85-kD M-CSF act on
monocytes, as described previously (22); thus, it can reasonably
be assumed that PG-M-CSF modulates LDL metabolism in
macrophages.
Although the biologically active nature of PG-M-CSF and
its binding of LDL suggest that this molecule makes a profound
contribution to the atherosclerotic process, this contribution is
still speculative. However, our study offers a new opportunity
to study the nature of the interaction between PG and LDL and
the subsequent metabolism of such complexes in macrophages.
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